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In vitro norepinephrine significantly activates isolated platelets
from healthy volunteers and critically ill patients following
severe traumatic brain injury
Abstract
INTRODUCTION: Norepinephrine, regularly used to increase systemic arterial blood pressure and thus
improve cerebral perfusion following severe traumatic brain injury (TBI), may activate platelets. This,
in turn, could promote microthrombosis formation and induce additional brain damage. METHODS:
The objective of this study was to investigate the influence of norepinephrine on platelets isolated from
healthy volunteers and TBI patients during the first two post-traumatic weeks. A total of 18 female and
18 male healthy volunteers of different age groups were recruited, while 11 critically ill TBI patients
admitted consecutively to our intensive care unit were studied. Arterial and jugular venous platelets
were isolated from norepinephrine-receiving TBI patients; peripheral venous platelets were studied in
healthy volunteers. Concentration-dependent functional alterations of isolated platelets were analyzed
by flow cytometry, assessing changes in surface P-selectin expression and platelet-derived
microparticles before and after in vitro stimulation with norepinephrine ranging from 10 nM to 100
microM. The thrombin receptor-activating peptide (TRAP) served as a positive control. RESULTS:
During the first week following TBI, norepinephrine-mediated stimulation of isolated platelets was
significantly reduced compared with volunteers (control). In the second week, the number of P-selectin-
and microparticle-positive platelets was significantly decreased by 60% compared with the first week
and compared with volunteers. This, however, was associated with a significantly increased
susceptibility to norepinephrine-mediated stimulation, exceeding changes observed in volunteers and
TBI patients during the first week. This pronounced norepinephrine-induced responsiveness coincided
with increased arterio-jugular venous difference in platelets, reflecting intracerebral adherence and signs
of cerebral deterioration reflected by elevated intracranial pressure and reduced jugular venous oxygen
saturation. CONCLUSION: Clinically infused norepinephrine might influence platelets, possibly
promoting microthrombosis formation. In vitro stimulation revealed a concentration- and
time-dependent differential level of norepinephrine-mediated platelet activation, possibly reflecting
changes in receptor expression and function. Whether norepinephrine should be avoided in the second
post-traumatic week and whether norepinephrine-stimulated platelets might induce additional brain
damage warrant further investigations.
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Abstract
Introduction Norepinephrine, regularly used to increase
systemic arterial blood pressure and thus improve cerebral
perfusion following severe traumatic brain injury (TBI), may
activate platelets. This, in turn, could promote microthrombosis
formation and induce additional brain damage.
Methods The objective of this study was to investigate the
influence of norepinephrine on platelets isolated from healthy
volunteers and TBI patients during the first two post-traumatic
weeks. A total of 18 female and 18 male healthy volunteers of
different age groups were recruited, while 11 critically ill TBI
patients admitted consecutively to our intensive care unit were
studied. Arterial and jugular venous platelets were isolated from
norepinephrine-receiving TBI patients; peripheral venous
platelets were studied in healthy volunteers. Concentration-
dependent functional alterations of isolated platelets were
analyzed by flow cytometry, assessing changes in surface P-
selectin expression and platelet-derived microparticles before
and after in vitro stimulation with norepinephrine ranging from
10 nM to 100 μM. The thrombin receptor-activating peptide
(TRAP) served as a positive control.
Results During the first week following TBI, norepinephrine-
mediated stimulation of isolated platelets was significantly
reduced compared with volunteers (control). In the second
week, the number of P-selectin- and microparticle-positive
platelets was significantly decreased by 60% compared with
the first week and compared with volunteers. This, however, was
associated with a significantly increased susceptibility to
norepinephrine-mediated stimulation, exceeding changes
observed in volunteers and TBI patients during the first week.
This pronounced norepinephrine-induced responsiveness
coincided with increased arterio-jugular venous difference in
platelets, reflecting intracerebral adherence and signs of
cerebral deterioration reflected by elevated intracranial pressure
and reduced jugular venous oxygen saturation.
Conclusion Clinically infused norepinephrine might influence
platelets, possibly promoting microthrombosis formation. In vitro
stimulation revealed a concentration- and time-dependent
differential level of norepinephrine-mediated platelet activation,
possibly reflecting changes in receptor expression and function.
Whether norepinephrine should be avoided in the second post-
traumatic week and whether norepinephrine-stimulated platelets
might induce additional brain damage warrant further
investigations.
Introduction
In clinical routine, norepinephrine is used to increase and
maintain arterial blood pressure in predefined ranges with the
aim of improving organ perfusion. Apart from its vascular
smooth muscle cell α1 adrenergic targets mediating arteriolar
vasoconstriction with subsequent increase in arterial bloodPage 1 of 12
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receptors located on platelets [2]. Stimulation of α2a adrener-
gic receptors, in turn, could activate circulating platelets as
reflected by surface expression of CD62P (P-selectin), confor-
mational changes of the GPIIb/IIIa receptor, shedding of plate-
let-derived microparticles [3,4], and soluble adhesion
molecules (sP-selectin). These alterations, in turn, are capable
of activating platelets, leukocytes, and endothelial cells [5] in
a self-perpetuating manner. Thus, there is an increasing risk for
local microthrombosis formation, especially in the presence of
injured endothelial cells with local activation of platelets, fibrin
deposition, and binding of von Willebrand factor [2] with con-
comitant activation of immunocompetent cells [6]. Subse-
quently, this could promote ensuing edema progression and
cell damage in pre-injured organs. In this context, severe trau-
matic brain injury (sTBI) is associated with endothelial damage
and local microthrombosis formation which contribute to
impaired cerebral microcirculation [7-9]. These microcircula-
tory changes may be amplified by additional norepinephrine-
mediated platelet activation, adhesion, and aggregation since
norepinephrine with its α2a adrenergic stimulation of platelets
is routinely infused to elevate cerebral perfusion pressure
(CPP) following sTBI. Consequently, anticipated neuroprotec-
tion by increasing CPP might be compromised due to sus-
tained norepinephrine-induced platelet activation.
The aims of the present descriptive study were to assess
whether (a) norepinephrine increases signs of functional acti-
vation in isolated platelets in a concentration-dependent man-
ner, (b) there are differences between arterial and jugular
venous platelets, (c) these alterations are time-dependent dur-
ing the course of sTBI, and (d) arterio-jugular venous differ-
ences (AJVDs) are associated with signs of cerebral
worsening in critically ill patients suffering from sTBI. To this
end, changes in surface expression of P-selectin and intracel-
lular prothrombotic platelet-derived microparticles of isolated
platelets taken from healthy controls and sTBI patients were
determined by flow cytometry.
Materials and methods
To determine the potential stimulatory effects of norepine-
phrine on platelets, platelets were isolated from healthy con-
trols and patients suffering from sTBI. Following informed
written consent by the volunteers and the relatives of the sTBI
patients, respectively, blood samples were drawn from 36 vol-
unteers and 11 sTBI patients according to the protocol
approved by our local ethics committee.
The study was conducted from January to October 2006 at
the University Hospital of Zuerich. Patients were included if
they were sedated and had received an intracranial pressure
(ICP) probe and a jugular venous catheter. Continuous
assessment of jugular venous oxygen saturation (SjvO2) as
well as the intermittent analysis of arterio-jugular venous glu-
cose and lactate differences by routine blood gas analysis
were used to guide therapeutic interventions following sTBI.
Patients younger than 18 and older than 65 years were not
enrolled. Patients with a history of previous TBI as well as
intake of drugs known to influence platelet function (for exam-
ple, aspirin, ibuprofen, and clopidrogel) within 8 days before
trauma were excluded. Patients with a known history of alcohol
abuse, drug abuse, as well as metabolic disorders and renal/
hepatic dysfunction were also excluded.
Age- and gender-dependent influences
To rule out age- and gender-dependent influences, female and
male volunteers were grouped in three age clusters: 20 to 30,
31 to 40, and 41 to 50 years, with 6 volunteers per gender and
age cluster, resulting in a total of 36 volunteers.
Physiologic data
To ensure that recruited volunteers were healthy, a carefully
structured interview was conducted and various variables (for
example, blood pressure, pulse, temperature, and peripheral
oxygen saturation) were determined before platelets were iso-
lated and stimulated in vitro. Volunteers with a recent history
of fever, surgery, or intake of drugs possibly influencing plate-
let function (for example, aspirin and clopidrogel) were
excluded.
Blood samples
Volunteers
In healthy volunteers, blood was drawn once from the cubital
vein with 21-gauge needles. Blood was collected in commer-
cially available tubes containing 3.2% sodium citrate
(Sarstedt, Nümbrecht, Germany). While 2 mL was used to
determine differential blood count by the Institute for Clinical
Hematology at the University Hospital Zuerich, 4 mL was used
to investigate functional changes in isolated platelets. Approx-
imately 0.5 mL of blood was used for venous blood gases
using the Radiometer ABL 610® (Radiometer A/S, Brønshøj,
Denmark). Fasted volunteers were investigated between 8
and 10 a.m., following a resting period of 30 minutes upon
arrival. Blood sampling as well as questioning and assessment
of physiologic variables were performed by the same
investigator.
Patients
In sTBI patients, arterial and jugular venous blood (6 mL each)
was drawn using the same tubes as in the volunteers. Blood
samples were drawn once daily up to 2 weeks until removal of
the jugular venous catheter. Differential blood counts were
performed by the Institute for Clinical Hematology at the Uni-
versity Hospital Zuerich once daily, while platelets were iso-
lated and treated by a standardized protocol as outlined
below. Changes in cerebral metabolism were determined by
assessing alterations in glucose, lactate, and SjvO2 measured
by routine blood gas analysis of arterial and jugular venous
blood drawn at the same time point. Before the actual blood
samples used for laboratory and in vitro analysis were drawn,Page 2 of 12
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Available online http://ccforum.com/content/12/3/R80the first 2 mL of blood was discarded to minimize the potential
impact of local thrombus formation at the tip of the catheters
which could develop over time.
Intensive care unit treatment following severe traumatic 
brain injury
Following placement of an ICP probe, patients with sTBI were
treated in the intensive care unit (ICU) according to a stand-
ardized protocol. Routine treatment and decision making were
not influenced by the present investigations, and the obtained
data were not integrated in the current treatment concept.
Continuously infused midazolam (Dormicum® and fentanyl
(Sintenyl® were tapered according to ICP values. Volume and
norepinephrine administration were adjusted to maintain CPP
values above 70 mm Hg. Patients did not receive heparin or
low-molecular-weight heparin. All flush systems were main-
tained without heparin.
Isolation of platelets
Platelet activation was measured in platelet-rich plasma (PRP)
using monoclonal antibodies and three-color flow cytomtery.
Within 30 minutes of blood withdrawal, samples were centrif-
ugated at 5,000 rounds per minute for 15 minutes. Thereafter,
5 μL of PRP was added to a 12 × 75-mm tube containing 15
μL of each of the following fluorescent-labelled monoclonal
antibodies: CD61-fluorescein isothiocyanate and CD62P-
phycoerythrin. CD62P (P-selectin) is an antigen present on
the surface of activated platelets [10]. Anti-CD61 recognizes
the platelet glycoprotein receptor, GPIIIa, which is found on all
resting and activated platelets and which is used to identify
platelets.
After 20 minutes of incubation with monoclonal antibodies in
the dark at room temperature, 1 mL of 1% paraformaldehyde
was added to each tube for fixation of platelets. Mouse immu-
noglobulin G 1 (fluorescein isothiocyanate) and phycoerythrin
were used as isotype controls. Antibodies and isotype con-
trols were purchased from Becton Dickinson Immunocytome-
try Systems (San Jose, CA, USA). All samples were analyzed
within 90 minutes on a FACSscan flow cytometer (Becton
Dickinson, Mountain View, CA, USA) using Cell Quest® soft-
ware (Becton Dickinson Immunocytometry Systems). Flow
cytometer performance used to analyze microparticles was
verified employing 1-μm calibration beads (Bangs Laborato-
ries, Inc., Fishers, IN, USA).
A total of 5,000 CD61-positive events were collected with all
light scatter and fluorescence parameters in a logarithmic
mode. Platelets were gated on the basis of light scatter and
CD61 expression. Activated platelets were defined as the per-
centage of CD61-positive events expressing the activated
confirmation of P-selectin (CD62P). Platelet-derived micropar-
ticles were also measured and identified as CD61-positive
events in a gate obtained using uniform microspheres of 7.4
μm in diameter (Bangs Laboratories, Inc.).
Stimulation of isolated platelets
Double samples of isolated peripheral venous, jugular venous,
and arterial platelets were incubated for 20 minutes with differ-
ent norepinephrine concentrations (Noradrenaline Sintetica
0.1%; Sintetica S.A., Mendrisio, Switzerland) ranging from 10
nM to 100 μM. The same norepinephrine as employed in the
routine treatment in our ICU was used for the in vitro stimula-
tion. Thrombin receptor-activating peptide (TRAP) (Becton
Dickinson Immunocytometry Systems), known to maximally
activate platelets, served as a positive control. Upon stimula-
tion, changes in expression of P-selectin-positive platelets and
changes in the number of CD61-positive platelet-derived
microparticles were assessed to reveal the degree of platelet
activation. All samples were analyzed within 90 minutes after
blood withdrawal.
Analysis of differential blood counts
Differential blood counts were analyzed in the ISO-IEC 17025
accredited university hospital laboratory at the University Hos-
pital Zuerich.
Analysis of sP-selectin
sP-selectin was measured in plasma using a DuoSet® ELISA
[enzyme-linked immunosorbent assay] Development System
(R&D Systems, Inc., Minneapolis, MN, USA) in accordance
with the instructions of the manufacturer.
Assessment of mean arterial blood pressure, intracranial 
pressure, cerebral perfusion pressure, arterio-jugular 
venous differences, drug dosage, and hydroxyethyl 
starch
Continuously recorded ICP, CPP, temperature, and SjvO2
were assessed in 1-hour intervals. Drug dosage was also
determined in 1-hour intervals. A daily median was calculated
using these 24 values. Daily administration of hydroxyethyl
starch (HES) (Voluven® was recorded. AJVDs in glucose and
lactate were assessed in 4- to 6-hour intervals, allowing us to
calculate a daily median. AJVDs in platelets, leukocytes, and
sP-selectin were measured once daily.
Calculation of arterio-jugular venous differences
Jugular venous values were substracted from arterial values,
thus yielding the calculated AJVDs. Positive AJVDs reflect cer-
ebral retention or uptake as the arterial levels exceed the jug-
ular venous concentration. Negative AJVD values reveal
sustained release or decreased uptake/binding within the cer-
ebral compartment as jugular venous levels exceed arterial
concentrations.
Statistical analysis
Results are presented as median or mean ± standard error of
the mean, where applicable. Differences between groups,
time points, and norepinephrine concentrations were rated
significant at a probability level of less than 0.05 using analysis
of variance on ranks with post hoc multiple pairwisePage 3 of 12
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Stat® 3.5 (SPSS Inc. Headquarters, Chicago, Illinois, USA).
Figures were created with SigmaPlot® 10.0 (SPSS Inc. Head-
quarters, Chicago, Illinois, USA).
Results
Healthy controls
Physiologic and laboratory values
Physiologic data and laboratory values revealing that all 36 vol-
unteers were healthy are presented in Table 1. Since there
were no age- or gender-related differences (data not shown),
data of all volunteers were pooled.
In vitro norepinephrine stimulation of isolated platelets
In vitro stimulation of isolated platelets with norepinephrine
showed a significant concentration-dependent increase in P-
selectin-positive (Figure 1) and microparticle-positive (Figure
2) platelets compared with isolated platelets which were not
stimulated by norepinephrine under baseline conditions. Incu-
bation with TRAP significantly and maximally increased P-
selectin and microparticle expression compared with baseline
values of unstimulated platelets (Figures 1 and 2). Overall,
there were no age- or gender-dependent differences (data not
shown).
Patients with severe traumatic brain injury
Demographic data of the investigated critically ill patients suf-
fering from sTBI are presented in Table 2. Changes in absolute
blood platelet and leukocyte counts, AJVDs of platelets, leuko-
cytes, glucose, and lactate as well as mean arterial blood pres-
sure, ICP, CPP, SjvO2, temperature, and average drug dosage
are presented in Table 3. Data were pooled for the first and
Figure 1
Effect of norepinephrine and thrombin receptor-activating peptide (TRAP) o  surface expression of P-selectin in pl telets isolated from healthy controls
(TRAP) on surface expression of P-selectin in platelets isolated from 
healthy controls. Norepinephrine, in a concentration-dependent man-
ner, increased the number of P-selectin-positive platelets, which was 
significant only at norepinephrine concentrations of greater than or 
equal to 10 μM. Maximal increase was induced with TRAP. +P <0.001 
TRAP versus norepinephrine; * P <0.001 norepinephrine of 10 and 
100 μM versus norepinephrine of less than 10 μM; analysis of variance 
on ranks.
Figure 2
Significant concentration-dependent influence of norepinephrine and thrombin re eptor-activating peptide (TRAP) on platelet microparticles isolated from healthy c trols
thrombin receptor-activating peptide (TRAP) on platelet microparticles 
isolated from healthy controls. This effect was significant only at nore-
pinephrine concentrations of greater than or equal to 10 μM with a 
maximal increase induced with TRAP. +P <0.001 TRAP versus nore-
pinephrine; * P <0.001 norepinephrine of 10 and 100 μM versus nore-
pinephrine of less than 10 μM; analysis of variance on ranks.
Table 1
Physiologic and laboratory data of 36 healthy volunteers
Parameters (normal values) Median ± SEM Range
Physiologic data
Body mass index, kg/m2 24 ± 0.5 17.3–34.4
Temperature, °C 36.8 ± 0.1 35.6–37.2
SpO2, percentage 98 ± 0.2 95–100
Heart rate, beats per minute 80 ± 2 56–101
MABP, mm Hg 99 ± 2 78–131
HCO3-, mM 26.7 ± 0.3 21.4–28.5
Glucose, mM 5.9 ± 0.13 4.1–8.2
Lactate, mM 1.3 ± 0.08 0.7–2.4
Differential blood count
Hemoglobin, g/dL (13.4–17.0) 14.1 ± 0.3 11.5–16.3
Platelets, 103/μL (143–400) 261 ± 12 190–411
Leukocytes, 103/μL (3.0–9.6) 5.9 ± 0.35 2.94–10.77
sP-selectin, ng/mL 63 ± 10 45–96
Due to absent differences, data from different age groups and 
gender were pooled. MABP, mean arterial blood pressure; SEM, 
standard error of the mean; SpO2, peripheral oxygen saturation.Page 4 of 12
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leukocyte counts were significantly increased. Whereas plate-
lets remained within normal limits, leukocytes surpassed the
upper limit of normal values. Whereas ICP was significantly
increased, CPP, SjvO2, and temperature were significantly
decreased during the second week compared with the first
week. These changes, however, remained within clinically
acceptable limits. Administered drug dosages were similar for
norepinephrine, midazolam, and fentanyl during the first and
second week. In a total of 751 SjvO2, CPP, and ICP values
which were recorded at the same time as jugular venous blood
gas analysis only 0.4% SjvO2 were less than 50%, 0.1% of
CPP values were less than 60 mm Hg, and 17% of ICP was
greater than 20 mm Hg. In eight of the 11 patients, pneumonia
was diagnosed on (a median of) 8.5 days after trauma (range
3 to 13 days). In 1 patient (#3), bacteremia with coagulase-
negative Staphylococcus aureus was diagnosed. In 1 multiply
injured patient (#8), pulmonary embolism was diagnosed clin-
ically and verified radiologically on day 12 after trauma after
the patient was mobilized. A deep venous thrombosis was not
found. A vena cava filter was inserted and removed after 14
days. Thereafter, the patient had an uneventful recovery.
Arterio-jugular venous differences
AJVDs for platelets showed predominantly positive values,
which increased significantly over time, exceeding the positive
values calculated during the first week. AJVD values for leuko-
cytes were predominantly negative and were significantly
decreased during the second week. The positive values for
AJVD in glucose showed a significant increase over time,
whereas the negative values for AJVD in lactate continued to
decrease during the second week. Contrary to the significant
findings in absolute platelet counts and AJVD in platelets, the
AJVD for sP-selectin remained unchanged despite a trend
toward higher values.
In vivo measurements of isolated platelets
During the second post-traumatic week, the number of P-
selectin-positive cells expressed as the relative amount of all
gated platelets was significantly reduced compared with
healthy controls and the first week (Figure 3). Similar changes
were also observed for CD61-positive microparticles (data not
shown). Incubation with TRAP, however, maximally increased
the relative amount of P-selectin-positive (Figure 4) and micro-
particle-positive (data not shown) platelets, which was mostly
Table 2
Demographic data of 11 consecutively investigated critically ill patients suffering from severe traumatic brain injury
Patient Age, years Gender Initial GCS Brain 
lesions
Additional 
injuries
AIS head ISS total Length JB, 
days
ICU stay, 
days
eGOS
1 23 Female 15 Mixed Thorax, skin 5 45 16 41 8
2 54 Male 3 Mixed - 5 25 5 16 7
3 32 Male 3 Mixed Thorax, 
extremities
5 57 24 51 7
4 41 Female 6 Mixed - 5 25 18 26 8
5 64 Male 6 Mixed Thorax, 
abdomen
5 45 7 10 1
6 53 Male 14 Multiple 
contusions
- 5 25 2 3 1
7 19 Male 12 Mixed - 5 25 20 27 7
8 49 Male 15 Isolated 
EDH
Thorax, 
spine, 
extremities
5 38 7 21 5
9 51 Male 15 Isolated 
EDH
Thorax, 
spine, 
extremities, 
pelvis, skin
4 41 4 16 5
10 41 Male 10 Mixed Thorax, 
spine, 
extremities
5 38 10 17 6
11 43 Male 14 Isolated 
contusion
Face, skin, 
extremities
5 33 6 12 7
Median, 
range
43, 23–64 2 females/9 
males
11, 3–15 7 mixed 
lesions
7 with 
additional 
injuries
5, 4–5 38, 25–57 7, 2–24 17, 3–51 7, 1–8
Due to individual clinical courses, the jugular venous catheter was removed at different days, resulting in a lower number of patients during the 
second week (n = 5 versus n = 11, first week). AIS, abbreviated injury score; EDH, epidural hematoma; eGOS, extended Glasgow Outcome 
Score; GCS, Glasgow Coma Scale score determined at the site of accident; ICU, intensive care unit; ISS, injury severity score; JB, jugular bulb.Page 5 of 12
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4). Overall, there was no significant difference between arterial
and jugular venous platelets (Figures 3 and 4).
In vitro norepinephrine stimulation of isolated platelets
Upon incubation with norepinephrine, the expression of P-
selectin-positive (Figure 4) and microparticle-positive (data
not shown) platelets was significantly increased in a concen-
tration-dependent manner compared with baseline values of
freshly isolated platelets which were not stimulated. During the
first week, however, this response was significantly attenuated
compared with healthy controls. During the second week,
norepinephrine-mediated increase in P-selectin-positive and
microparticle-positive platelets significantly exceeded the
changes observed during the first week and the correspond-
ing alterations found in volunteers. Overall, there was a trend
Table 3
Changes in laboratory and clinical variables following severe traumatic brain injury
First week Second week P value
Laboratory values
Platelets, × 103/μL 150 ± 6 215 ± 10a <0.001
Lowest values 128 ± 14; day 1
Highest values 224 ± 23; day 14
Leukocytes, × 103/μL 8.7 ± 0.4 12.3 ± 1a <0.01
C-reactive protein, mg/L 121 ± 26 133 ± 23 NS
Interleukin-6, ng/L 142 ± 40 78 ± 21 NS
Calculated arterio-jugular venous differences
AJVD platelets, × 103/μL 1.5 ± 0.9 5.8 ± 2a <0.01
AJVD leukocytes, × 103/μL -0.12±0.05 -0.02±0.1a <0.03
AJVD glucose, mM 0.33 ± 0.02 0.43 ± 0.04a <0.04
AJVD lactate, mM -0.03±0.006 -0.06±0.01a <0.04
AJVD sP-selectin, pg/mL 454 ± 932 700 ± 1,254 NS
Neuromonitoring
Mean arterial pressure, mm Hg 97 ± 1 96 ± 1 NS
Intracranial pressure, mm Hg 13 ± 0.7 16 ± 0.5a 0.019
Cerebral perfusion pressure, mm Hg 83 ± 1 80 ± 1 NS
SjvO2, percentage 76 ± 1 69 ± 1a <0.001
Temperature, °C 36.2 ± 0.1 35.5 ± 0.1a <0.001
Pharmacologic treatment/platelet transfusions
Norepinephrine, μg/minute 7 ± 0.64 7.2 ± 1.03 NS
Fentanyl, mg/hour 0.6 ± 0.05 0.59 ± 0.08 NS
Midazolam, mg/hour 62 ± 5 59 ± 8 NS
Platelet transfusions, ml 300 ± 227 (n = 4) 0
HES 130/0.4, mL (Voluven®
Cumulative 11,935 ± 1,826a 3,000 ± 2,100 <0.001
Daily average 1,571 ± 260a 429 ± 300 <0.001
Positive arterio-jugular venous differences (AJVDs) reflect cerebral uptake, while negative AJVD values unmask release or decreased uptake/
binding. Values are expressed as mean ± standard error of the mean. aDifferences are rated significant at the corresponding levels of significance 
using the t test or Mann-Whitney test, respectively. a, significant differences; HES, hydroxyethyl starch; NS, not significant; SjvO2, jugular venous 
oxygen saturation.Page 6 of 12
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Available online http://ccforum.com/content/12/3/R80toward sustained stimulation in jugular venous compared with
arterial platelets (Figure 4) which, however, did not reach sta-
tistical significance, due to the low number of patients (n = 5).
Discussion
Under in vitro conditions, incubating isolated platelets with
norepinephrine significantly and concentration-dependently
increased the expression of surface P-selectin and intracellular
prothrombotic microparticles, reflecting increased platelet
activation. Interestingly, this response revealed a differentiated
temporal profile in critically ill sTBI patients with a significantly
reduced stimulation during the first week, followed by a sus-
tained stimulatory effect during the second week. This coin-
cided with a marked increase in circulating platelet count and
in cerebral platelet retention reflected by positive AJVD values.
This, however, was not associated with an increase in jugular
venous sP-selectin concentrations. Despite a trend, there was
no significant difference in the norepinephrine-mediated stim-
ulation between arterial and jugular venous platelets. In addi-
tion, signs of cerebral deterioration (that is, elevated ICP,
decreased SjvO2, and increased cerebral lactate production)
coincided with the sustained norepinephrine-mediated plate-
let activation in the second post-traumatic week.
Sampling and isolation procedure
Arterial and jugular venous catheters remain in place until
these catheters can or need to be removed. Over time, local
thrombus formation at the tip of the catheter is possible. New
daily insertions of catheters to avoid any local thrombus forma-
tion, however, are not feasible under clinical conditions due to
hemodynamic instability, generalized edema formation related
to capillary leakage, and a limited number of accessible ves-
sels. Local thrombus formation at the tip of the catheters acti-
vates platelets, possibly resulting in false-positive results. As a
standardized procedure to reduce the risk of possible throm-
bus-related confounding influences, 2 mL of blood was with-
drawn and discarded before the actual blood sample was
taken. Nevertheless, local activation might have occurred, pos-
sibly explaining the reduced number of P-selectin-expressing
platelets during the second week. In addition to local catheter-
related effects, the underlying tissue damage might have con-
tributed to platelet activation with subsequent P-selectin shed-
ding and sustained sP-selectin concentrations. Due to the fact
that the post-traumatic significantly increased sP-selectin lev-
els exceeded normal values by several fold, any additional
shedding might remain obscured. In addition, isolation proce-
dures can activate cells. As to our own preliminary experi-
ments, the chosen isolation procedure is associated with an
activation of less than 2%.
Changes in platelet function following trauma
As shown by Scherer and Spangenberg [11], Jacoby and col-
leagues [12], and Nekludov and colleagues [13,14], plasmatic
coagulation, platelet count, and platelet function are signifi-
cantly and reversibly altered during the early phase following
sTBI. In this context, activation of the coagulation cascade
which occurs within the first hours after trauma within the
injured brain [11,13] as reflected by an elevated transcranial
gradient precedes systemic hypercoagulability which is fol-
lowed by fibrinolytic activity. These alterations, in turn, could
explain the observed decrease in platelet count and fibrinogen
level and subsequent increase in thrombin-antithrombin III
complex, prothrombin fragment F1+2, and D-dimer concentra-
tions [11]. Following TBI, platelets were significantly activated
in the face of depressed function as reflected by prolonged
collagen/epinephrine closure times during the first 3 post-trau-
matic days [12]. In addition, prolonged disturbance in platelet
function was significantly sustained in non-surviving patients,
which underlines the pathophysiologic importance of dis-
turbed coagulation. In conjunction with a prolonged bleeding
time, platelets showed a decreased responsiveness to arachi-
donic acid as determined by thromboelastography [14]. As
shown by the present study, functional depression in isolated
platelets is expanded to 7 days following sTBI and reflects pro-
longed functional disturbance in thrombocytic coagulation.
Clinically, however, there were no signs of coagulation disor-
der. Following the initial functional depression, platelet func-
tion was significantly increased in the second week following
sTBI, which coincided with sustained cerebral retention of
platelets and signs of disturbed cerebral perfusion. Thus,
these changes clearly unmask temporally differentiated
changes in platelet function which are of pathophysiologic
importance.
Figure 3
Changes in expression of surface P-selectin in platelets isolated from severe traumatic brain injury p ti nts compared wi h healthy contr ls
severe traumatic brain injury patients compared with healthy controls. 
The relative number of P-selectin-positive arterial and jugular venous 
platelets was significantly decreased during the second week. * P 
<0.05 versus controls and first week; analysis of variance on ranks.Page 7 of 12
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Under physiologic conditions, quantitative and qualitative fea-
tures of platelets are tightly controlled by various mediators
within the bone marrow, blood, and along the endothelial cells
[15]. Following injury, excessive loss and consumption of
platelets exceeding production and release from bone marrow
result in a significant decrease in circulating platelets, reaching
its nadir by the second post-traumatic day. Subsequent signif-
icant increase reflects upregulated compensatory production
within the bone marrow aimed at normalizing the amount of cir-
culating platelets. In this context, thrombopoietin is of crucial
importance [16]. Thrombopoietin also contributes to
enhanced platelet activation under clinical conditions [17].
Newly produced and freshly released platelets might be acti-
vated more easily than senescent platelets. This, in turn, might
explain the preserved and exaggerated in vitro norepinephrine-
mediated stimulation during the second week as observed in
the present study. The preserved functionality in platelets
despite decreased baseline P-selectin expression as found in
the second week is in line with results from Michelson and col-
leagues [18], who showed that circulating platelets remain
active for at least 24 hours following shedding of surface P-
selectin. In this context, we suggest that reduced P-selectin-
positive platelets in the face of signs of cerebral worsening
reflect functional disturbance of the isolated platelets, assum-
ing that platelets contribute to pathophysiologic cascades
within the injured brain in these patients. While P-selectin
expression determines size and stability of platelet aggregates
[19], reduced surface P-selectin expression does not imply
functional impairment [18]. Shedding of P-selectin reflects
previous platelet activation and could result in facilitated
release of various toxic mediators [20,21] which have been
shown to induce and promote tissue damage. This warrants
further investigations.
Norepinephrine-mediated activation of platelets
Activation of α2 adrenergic receptors by norepinephrine rou-
tinely infused to elevate CPP following sTBI enhanced platelet
aggregability concentration dependently and increased plate-
let secretion of beta-thromboglobulin during high-dose infu-
sion [22]. In addition, norepinephrine stimulated the
expression of surface P-selectin and intracellular prothrom-
botic microparticles. Stimulation of different surface receptors
results in a stereotypic amplified activation of intracellular G-
protein-mediated cascades involving the Rho/Rho-kinase
pathway, phospholipase C, and protein kinase C, which are
essential for conformational changes in platelet shape as well
as aggregation and degranulation [23].
Despite the tedious analysis and difficult interpretation of con-
centrations of blood norepinephrine (due to its short half-life
and fast response to changes in infusion parameters), John-
ston and colleagues [24] determined the pharmacokinetic
profile of norepinephrine in eight patients suffering from sTBI.
Figure 4
Relative increases in norepinephrine-induced expression of P-selectin in arterial (black bars) and jugular venous (grey bars) platelets isolated from severe traumatic brai  injury (TBI) patients and peripheral venous platelets taken from healthy controls (white bars) xpressed as a percentage f bas lin  values
severe traumatic brain injury (TBI) patients and peripheral venous platelets taken from healthy controls (white bars) expressed as a percentage of 
baseline values. Baseline values were determined in platelets not stimulated in vitro with norepinephrine. During the first week, the norepinephrine-
mediated increase in P-selectin-positive platelets was significantly reduced compared with controls. In the second week, the norepinephrine-medi-
ated increase in P-selectin expression significantly exceeded changes seen in the first week and in healthy volunteers. Overall, there was no signifi-
cant difference between arterial and jugular venous platelets. During the second week, the TRAP-mediated increase in P-selectin-positive platelets 
significantly exceeded the TRAP-induced activation observed during the first week. #P <0.001 second week versus first week; +P <0.01 patients 
versus controls; * P <0.01 norepinephrine of greater than 500 nM versus norepinephrine of less than 10 μM. TRAP, thrombin receptor-activating 
peptide.Page 8 of 12
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cantly correlated with the rate of norepinephrine infusion dur-
ing steady-state conditions of the norepinephrine infusion
period. The average norepinephrine dose infused in the pres-
ently investigated patients ranged from 0.1 ± 0.07 to 0.16 ±
0.11 μg/kg per minute. Assuming a similar norepinephrine dis-
tribution volume and clearance in our patients, we are to
expect plasma levels of between 22.98 ± 16.98 and 37.08 ±
20.15 nM/L according to the results published by Johnston
and colleagues [24].
Based on the assumptions that norepinephrine exhibits mini-
mal regional and temporal fluctuations during steady-state
conditions and that in vitro concentrations are equally potent
as those in vivo, it appears as if extremely high norepinpehrine
doses were required to activate isolated platelets. The lowest
norepinephrine concentration associated with a significant
effect in the presently isolated platelets was 500 nM, which
exceeded the extrapolated blood levels of 25 nM by 20-fold.
Thus, it remains unclear to what extent the observed effects
are also valid under in vivo conditions.
The fact that isolated platelets exhibited a temporally differen-
tiated response to the same norepinephrine concentration in
the first versus second week coinciding with a preserved and
even increased TRAP-mediated platelet activation suggests
altered susceptibility of platelet receptors. In this context, func-
tional adaptation of platelet α2 adrenergic receptors in terms
of receptor downregulation or upregulation might be of phar-
macologic and pathophysiologic importance. Clinical as well
as experimental studies have shown that elevated catecho-
lamine concentrations are associated with a reduction in
expression and affinity of α2 adrenergic receptors [25-28].
This also resulted in a decreased platelet aggregation
response to epinephrine [29]. Intracellular adaptive processes
in conjunction with regained sensitization of previously desen-
sitized α2 adrenergic receptors might lead to the observed
sustained in vitro stimulation during the second week during
continuous norepinephrine stimulation following the
depressed stimulation during the first week. This could also
account for the stimulatory effect at a lower norepinephrine
concentration compared with healthy controls (500 nM versus
10 μM).
Influence of sedation
Sedative agents (for example, midazolam) might have contrib-
uted to the decreased expression of platelet surface P-selectin
as shown by Tsai and colleagues [30] and Gries and col-
leagues [31]. The inhibitory mechanism of midazolam is best
explained by concentration-dependent blocking of platelet
aggregation, inhibition of phosphoinositide breakdown and
intracellular Ca+2 mobilization, increased formation of cyclic
AMP, inhibition of increases in intracellular pH, and attenuated
protein kinase C activation [32]. Adaptive intracellular proc-
esses upon initial midazolam-induced functional depression
might have contributed to the sustained norepinephrine-medi-
ated stimulation of platelets isolated during the second week
despite the administration of amounts comparable to those in
the first week.
Influence of inflammation
Whether inflammation-induced cytokine release might have
contributed to the sustained in vitro stimulation of isolated
platelets appears doubtful since interleukin (IL)-6 levels were
not significantly increased during the second week in the pres-
ently investigated patients despite significant leukocytosis.
This is in line with findings reported by Leytin and colleagues
[33] showing that the pro-inflammatory cytokines IL-1β, IL-6,
and IL-8 did not stimulate platelets and failed to promote
thrombin-mediated platelet activation. Other mechanisms
related to bacterial infections, however, have been shown to
activate platelets, a circumstance that was not reflected by an
increase in leukocytes [34]. In those 8 patients with pneumo-
nia and the single patient with bacteremia, there was no signif-
icant difference in baseline P-selectin expression and
susceptibility to norepinephrine-mediated stimulation of iso-
lated platelets compared with the remaining 5 patients. An
inflammation-induced influence, however, needs to be specifi-
cally addressed in a larger study population.
Influence of hydroxyethyl starch solutions
In clinical routine, colloids (for example, HES) are combined
with cristalloids to maintain adequate organ perfusion and to
reduce catecholamine dose by inducing normovolemia. As
reported by Chen and colleagues [35], HES 130/0.4 (Volu-
ven®, which is routinely used in our ICU, induced transient
reduction in platelet-mediated coagulation reflected by
decreased platelet membrane glycoprotein and P-selectin
expression in patients undergoing elective minor surgery.
Under in vitro conditions, HES 130/0.4 did not influence the
expression of various membrane proteins on platelets isolated
from healthy volunteers [36]. Thus, decreased baseline P-
selectin expression observed in the second week does not
appear to be induced by HES since patients required signifi-
cantly less HES 130/0.4 compared with the first week. In fact,
baseline P-selectin and microparticle expression were compa-
rable to healthy volunteers during the first week despite a sig-
nificantly larger amount of HES 130/0.4 administered per day
compared with the single administration of HES 130/0.4 dur-
ing minor surgery as studied by Chen and colleagues [35].
Microthrombosis, platelet activation, and secondary 
brain injury
Following TBI, impaired pericontusional microcirculation
shows a dynamic temporal and heterogeneous regional profile
with impaired as well as increased cerebral perfusion [37,38].
Impaired perfusion is related to vasoconstriction and endovas-
cular occlusion due to microthrombosis evolving within the
first 24 hours and promoting edema formation. Under experi-Page 9 of 12
(page number not for citation purposes)
Critical Care    Vol 12 No 3    Tschuor et al.mental conditions, thrombotic occlusion is followed by spon-
taneous resolution during the second post-traumatic day as
evidenced by histology, intravital microscopy, and laser Dop-
pler flowmetry [7-9,39,40].
Sustained platelet adhesion and activation are functionally
interwoven with activated leukocytes, thereby facilitating
thrombus formation as well as attraction and tissue penetra-
tion of various leukocyte subpopulations [6]. This, in principle,
enables and promotes tissue repair. Upon excessive stimula-
tion, however, platelet-induced attraction and activation of leu-
kocytes can aggravate underlying tissue injury in conjunction
with evolving microthrombosis formation, thereby promoting
perpetuating autodestructive cascades.
Whether the increased platelet count in conjunction with leu-
kocytosis, sustained norepinephrine-mediated platelet activa-
tion, and increased retention of platelets within the brain
(positive arterio-jugular venous platelet difference) contributed
to the signs of cerebral deterioration as reflected by elevated
ICP, decreased SjvO2, and sustained lactate release during
the second week remains unclear.
Based on findings obtained in other neurodegenerative dis-
eases, activated platelets could be of increasing pathophysio-
logic importance also following clinical TBI. As reported by
Mathew and colleagues [41], transcerebral activation of plate-
lets occurred following the release of aortic crossclamp in
patients subjected to cardiac surgery and was associated with
neurocognitive worsening. Altered platelet function resulting in
impaired uptake and sustained release of glutamate might also
promote cerebral injury as discussed for cerebral ischema
[42], migraine [43], and epilepsy [44].
The finding of norepinephrine-mediated increased platelet
activation during the second week with a significantly attenu-
ated effect during the first week does not automatically imply
functional disturbance of platelets resulting in additional hem-
orrhage or contusion growth. Further analysis, however, is
required to determine norepinephrine-induced release of
platelet-derived toxic mediators despite nearly unchanged
expression of P-selectin in the early phase following sTBI.
Conclusion
The present results clearly demonstrate that in vitro stimula-
tion of isolated platelets is required to unmask functional alter-
ations that are missed when considering only P-selectin and
microparticle expression of non-stimulated platelets. At
present, it remains unclear whether the observed alterations
are of clinical importance since only norepinephrine in high
concentrations exceeding clinically relevant plasma levels
(>25 nM) increased the expression of surface P-selectin and
intracellular microparticles in isolated platelets. The differenti-
ated temporal profile of altered platelet activation could result
from functional downregulation of α2 receptors during the first
week followed by upregulation of α2 receptors during the
second week, possibly explaining the preceding depressed
and subsequent sustained stimulatory effect of in vitro nore-
pinephrine on isolated platelets, respectively. Coinciding with
the increased norepinephrine-mediated stimulation of isolated
platelets, platelets appeared to adhere to cerebral endothelial
cells during the second week as reflected by the positive AJVD
in platelets. In addition, signs of cerebral worsening were
encountered. Whether these findings are merely coincidental
or indeed are of pathophysiologic and therapeutic importance
needs to be investigated. It also remains to be determined
whether norepinephrine should be avoided or limited to a cer-
tain dose during the second week to prevent norepinephrine-
mediated platelet activation with its subsequent potentially
adverse tissue-damaging effects. Future research should also
investigate the pharmacodynamic profile of, for example, phe-
nylephrine and the effects of additional administration of spe-
cific α2 adrenergic inhibitors such as, for example, yohimbine.
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Key messages
• In vitro stimulation of isolated platelets unmasks func-
tional changes.
• Norepinephrine, in a concentration-dependent manner, 
stimulates isolated platelets in healthy volunteers and 
critically ill patients with severe traumatic brain injury.
• Stimulation was similar in arterial and jugular venous 
platelets.
• Isolated platelets express a temporally heterogeneous 
susceptibility to norepinephrine-mediated stimulation, 
reflected by a decreased response during the first week 
followed by an increased stimulation in the second 
week.
• In the second week, increased platelet susceptibility to 
norepinephrine-mediated stimulation coincided with 
signs of cerebral worsening.Page 10 of 12
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